Abstract 581P
Background
Afatinib is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that is widely used to treatfor EGFR-mutated non-small cell lung cancer (NSCLC). The association between afatinib-related adverse events (AEs) and survival outcomes in patients with NSCLC has been rarely reported.
Methods
We retrospectively reviewed treatment-naȉive patients with NSCLC treated with afatinib for ≥1 month at Chang Gung Memorial Hospital. We analyzed the association between different types of AEs and clinical outcomes, including progression-free survival (PFS) and overall survival (OS).
Results
This study included 599 patients. The patients who experienced any grades of AEs had longer OS (median OS = 27.2 vs. 14.0 months, p = 0.019) than those who did not. As for PFS did not differ significantly between these two groups. Regarding the types of AE, the patients with either paronychia (median PFS =, 16.0 vs. 12.4 months, p = 0.011), skin lesions (median PFS =, 15.4 vs. 12.1 months, p = 0.042), or gastrointestinal (GI) symptoms, including nausea/vomiting (median PFS =, 18.8 vs. 14.3 months, p = 0.016), had experienced significantly better PFS than patients without these AEs. In addition, the patients with either paronychia (median OS =, 31.0 vs. 21.0 months, p < 0.001), skin lesions (median OS =, 29.3 vs. 20.9 months, p < 0.001), pruritus (median OS =, 31.6 vs. 24.7 months, p < 0.001), or mucositis/oral ulcers (median OS =, 30.2 vs. 25,5 months, p < 0.023) had showed better OS than patients without these AEs. After adjustment, the patients with experiencing paronychia and GI symptoms had favorable PFS, and those with paronychia, skin lesions, pruritus, or mucositis/oral ulcers had favorable OS.
Conclusions
Patients with NSCLC treated with patients undergoing afatinib and experiencing adverse events (AEs) had favorable survival PFS and OS. In addition, the associations between afatinib-related AEs and survival outcomes were type-dependent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract